Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The development of novel peptidic and peptidomimetic therapies for the treatment

Award Number: R15DK098109
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2012
PERIOD OF PERFORMANCE END DATE: 08/31/2016

Group Awards By:

View Award Description

The development of novel peptidic and peptidomimetic therapies for the treatment - DESCRIPTION (provided by applicant): Sickle-cell disease (SCD) is a genetic blood disorder that is characterized by the presence of sickle-shaped red blood cells. These "sickled" cells clog small capillaries, leading to severe pain and organ damage [2]. The disease is the result of a single point mutation in the gene coding for the ¿-chain of hemoglobin (Hb), leading to the incorporation of a valine surface residue in place of glutamic acid [1]. Under low oxygen conditions, a binding surface for the valine residue is revealed at the EF-helix interface also on the ¿-chain. An intermolecular interaction occurs leading to polymerization of deoxygenated sickle-cell hemoglobin (HbS) and the characteristic sickling of the red blood cells (RBCs) [1]. Despite the fact that the molecular mechanism of SCD is well understood, no effective treatment exists [4]. Therefore, the discovery of molecules capable of preventing HbS polymerization would be highly desirable. Peptides and peptidomimetics have proven to be powerful tools for the manipulation of biological systems in a number of different contexts. Most relevant is their ability to bind to protein surfaces and disrupt key protein interactions [18-20, 30]. Several techniques are currently available for the discovery of peptidic and peptidomimetic compounds capable of serving as protein ligands [14,15]. The research plan for the development of novel therapeutics for sickle cell disease is three-fold. (1) Several one-bead-one- compound solid-phase libraries will be screened against HbS. The libraries are designed to bind to HbS in a manner capable of leading to the disruption of the key contact sites that lead to HbS polymer formation. It is hypothesized that these molecules will disrupt HbS polymerization. (2) Phage display libraries will be screened against oxygenated HbS, leading to the discovery of molecules that stabilize oxyhemoglobin, thereby preventing fiber formation. (3) Characterization of the ligands by fluorescence spectroscopy and photo-crosslinking will provide valuable information on the important contacts and allow for the synthesis of more potent second-generation ligands. This work represents a novel approach for development of therapeutics for this disease and provides an ideal training ground for undergraduate students, both of which fit the objectives of the R15 funding mechanism. PUBLIC HEALTH RELEVANCE: Sickle cell disease affects nearly 100,000 people in the United States, yet an effective treatment does not yet exist. Because of its relative low occurrence, it has not garnered significant attention from the pharmaceutical industry. The research proposed is the first step in defining the feasibility of a new strategy for treating this disorder through the use of modern screening and selection techniques.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2012	ILLINOIS WESLEYAN UNIVERSITY	1312 N PARK ST	BLOOMINGTON	IL	61701	MCLEAN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	12/15/2016	NEW	$0
														Subtotal = $0

Issue Date FY: 2012 ( Subtotal = $285,189 )
2012	2012	ILLINOIS WESLEYAN UNIVERSITY	1312 NORTH PARK	BLOOMINGTON	IL	61701	MCLEAN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/6/2012	NEW	$285,189
														Subtotal = $285,189

Grand Total All Awards = $285,189

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The development of novel peptidic and peptidomimetic therapies for the treatment

Award Number: R15DK098109

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2012

PERIOD OF PERFORMANCE END DATE: 08/31/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer